已收盘 09-04 16:00:00 美东时间
-0.003
-0.84%
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 85.37 percent increase over losses of $(0.82) per share from the same period last year.
08-07 19:49
Soligenix ( ($SNGX) ) just unveiled an update. On June 10, 2026, Soligenix rece...
06-13 05:05
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted
06-08 19:34
Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development PRINCETON, N.J., June 8, 2026 /PRNewswire/ -- Soligenix, ...
06-08 19:30
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
06-06 02:24
Soligenix ( ($SNGX) ) has issued an announcement. On May 28, 2026, Soligenix, I...
05-29 07:15
Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares rose 7% in pre-market trading as Q2 guidance exceeded expectations.
05-27 17:10
https://www.cdc.gov/ebola/situation-summary/index.html
05-18 23:25